Timothy P. Walbert Sells 320,174 Shares of Horizon Therapeutics PLC (NASDAQ:HZNP) Stock

Horizon Therapeutics PLC (NASDAQ:HZNP) CEO Timothy P. Walbert sold 320,174 shares of the firm’s stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $28.02, for a total transaction of $8,971,275.48. Following the transaction, the chief executive officer now directly owns 892,483 shares in the company, valued at $25,007,373.66. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Timothy P. Walbert also recently made the following trade(s):

  • On Wednesday, August 21st, Timothy P. Walbert sold 56,836 shares of Horizon Therapeutics stock. The shares were sold at an average price of $28.00, for a total transaction of $1,591,408.00.
  • On Thursday, August 22nd, Timothy P. Walbert sold 58,820 shares of Horizon Therapeutics stock. The shares were sold at an average price of $28.00, for a total transaction of $1,646,960.00.

Shares of HZNP stock opened at $27.40 on Friday. The firm has a market cap of $5.34 billion, a price-to-earnings ratio of 14.97, a P/E/G ratio of 1.66 and a beta of 0.83. The company has a debt-to-equity ratio of 0.90, a quick ratio of 2.12 and a current ratio of 2.20. Horizon Therapeutics PLC has a 52 week low of $16.56 and a 52 week high of $29.44. The firm’s 50-day simple moving average is $26.96 and its two-hundred day simple moving average is $25.71.

Horizon Therapeutics (NASDAQ:HZNP) last announced its quarterly earnings data on Wednesday, August 7th. The biopharmaceutical company reported $0.52 EPS for the quarter, topping the consensus estimate of $0.38 by $0.14. The business had revenue of $320.60 million for the quarter, compared to analyst estimates of $296.27 million. Horizon Therapeutics had a net margin of 5.90% and a return on equity of 30.33%. The company’s revenue for the quarter was up 5.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.48 earnings per share. Analysts forecast that Horizon Therapeutics PLC will post 1.59 earnings per share for the current year.

A number of research analysts recently weighed in on the stock. Stifel Nicolaus set a $35.00 price target on shares of Horizon Therapeutics and gave the company a “buy” rating in a research report on Friday, September 13th. Cowen set a $35.00 price target on shares of Horizon Therapeutics and gave the company a “buy” rating in a research report on Wednesday, August 7th. Piper Jaffray Companies set a $33.00 price target on shares of Horizon Therapeutics and gave the company a “buy” rating in a research report on Monday, August 26th. BidaskClub lowered shares of Horizon Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, September 6th. Finally, Bank of America assumed coverage on shares of Horizon Therapeutics in a research report on Thursday, September 26th. They set a “buy” rating and a $34.00 price target on the stock. Four research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $33.67.

A number of hedge funds have recently made changes to their positions in HZNP. FMR LLC raised its position in Horizon Therapeutics by 165.1% in the first quarter. FMR LLC now owns 5,205,217 shares of the biopharmaceutical company’s stock worth $137,575,000 after acquiring an additional 3,242,071 shares during the period. Nuveen Asset Management LLC increased its stake in shares of Horizon Therapeutics by 1,910.0% in the second quarter. Nuveen Asset Management LLC now owns 1,672,839 shares of the biopharmaceutical company’s stock worth $40,249,000 after purchasing an additional 1,589,614 shares in the last quarter. Price T Rowe Associates Inc. MD increased its stake in shares of Horizon Therapeutics by 1,774.4% in the second quarter. Price T Rowe Associates Inc. MD now owns 1,101,748 shares of the biopharmaceutical company’s stock worth $26,508,000 after purchasing an additional 1,042,969 shares in the last quarter. Rhenman & Partners Asset Management AB purchased a new position in shares of Horizon Therapeutics in the third quarter worth about $27,911,000. Finally, Renaissance Technologies LLC increased its stake in shares of Horizon Therapeutics by 11.4% in the second quarter. Renaissance Technologies LLC now owns 8,754,275 shares of the biopharmaceutical company’s stock worth $210,628,000 after purchasing an additional 896,500 shares in the last quarter. 86.29% of the stock is currently owned by institutional investors and hedge funds.

About Horizon Therapeutics

Horizon Therapeutics Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. Its orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of multiple conditions, rheumatoid arthritis; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.

Featured Story: What is the price-to-earnings growth (PEG) ratio?

Insider Buying and Selling by Quarter for Horizon Therapeutics (NASDAQ:HZNP)

Receive News & Ratings for Horizon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.